1、novotech-Obesity-Global Clinical Trial Landscape(2025)GLP-1-based therapies,led by drugs like Wegovy and Rybelsus,domi-nate the obesity drug pipelineEmerging dual/tri-ple agonists like retatrutide and cagrisema reflect a shift toward multi-target obe-sity treatmentsCountries like the United States,M

2、ainland China,South Korea,Germany,and Australia,emerged as top locations for conducting trials.OBESITY TRIAL CONTRIBUTIONSObesity is a chronic disease charac-terized by excessive fat accumu-lation that poses signifi-cant health risksThe content of this publication is proprietary to Novotech Health H

3、oldings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or other electronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commer

4、cial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials or intellectual property owned by Novotech.Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal

5、action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovotech-OBESITY GLOBAL CLINICAL TRIAL LANDSCAPE(2025)#DYK Did youknow?The United States is one of the leading countries in the Americas for adult overweight and obesity prevalenceThe UK leads ma

6、jor European countries in adult overweight and obesity prevalence,followed by Russia and GermanyThe Western Pacific region is witnessing a rising prevalence of obesity,with Australia and New Zealand among the most impactedSoutheast Asia shows lower obesity prevalence,with rising rates in Thailand,Ch